Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases

被引：26
作者：
Pizano-Martinez, Oscar [1 ,2 ,3 ]
Mendieta-Condado, Edgar [4 ]
Vazquez-Del Mercado, Monica [1 ,3 ,5 ]
Martinez-Garcia, Erika Aurora [1 ,3 ,6 ]
Chavarria-Avila, Efrain [1 ,7 ]
Ortuno-Sahagun, Daniel [5 ,8 ]
Marquez-Aguirre, Ana Laura [5 ,9 ]
机构：
[1] Univ Guadalajara, Ctr Univ Ciencias Salud, Inst Invest Reumatol & Sistema Musculo Esquelet II, Guadalajara 44340, Jal, Mexico
[2] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Morfol, Guadalajara 44340, Jal, Mexico
[3] Univ Guadalajara, Ctr Univ Ciencias Salud, Cuerpo Academ UDG CA 703, Guadalajara 44340, Jal, Mexico
[4] Secretaria Salud Jalisco, Lab Estatal Salud Publ LESP, Zapopan 46170, Jal, Mexico
[5] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Biol Mol & Genom, Guadalajara 44340, Jal, Mexico
[6] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Fisiol, Guadalajara 44340, Jal, Mexico
[7] Univ Guadalajara, Ctr Univ Ciencias Salud, Dept Disciplinas Filosof Metodol & Instrumentales, Guadalajara 44340, Jal, Mexico
[8] Univ Guadalajara, Ctr Univ Ciencias Salud, Inst Invest Ciencias Biomed IICB, Guadalajara 44340, Jal, Mexico
[9] Ctr Invest & Aistencia Tecnol & Diseno Estado Jali, Unidad Biotecnol Med & Farmaceut, Guadalajara 44270, Jal, Mexico
来源：
JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 09期
关键词：
autoimmune rheumatic diseases; anti-drug antibodies; biological agents; immunogenicity; MONOCLONAL-ANTIBODY; CERTOLIZUMAB PEGOL; NEUTRALIZING ANTIBODIES; INFLAMMATORY DISEASES; ARTHRITIS PATIENTS; LOW IMMUNOGENICITY; TNF INHIBITORS; DOUBLE-BLIND; EFFICACY; SAFETY;
D O I：
10.3390/jcm12093271
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Autoimmune rheumatic diseases are a cluster of heterogeneous disorders that share some clinical symptoms such as pain, tissue damage, immune deregulation, and the presence of inflammatory mediators. Biologic disease-modifying antirheumatic drugs are some of the most effective treatments for rheumatic diseases. However, their molecular and pharmacological complexity makes them potentially immunogenic and capable of inducing the development of anti-drug antibodies. TNF inhibitors appear to be the main contributors to immunogenicity because they are widely used, especially in rheumatoid arthritis. Immunogenicity response on these treatments is crucial since the appearance of ADAs has consequences in terms of safety and efficacy. Therefore, this review proposes an overview of the immunogenicity of biological agents used in autoimmune rheumatic diseases highlighting the prevalence of anti-drug antibodies.
引用
收藏
页数：18
相关论文
共 113 条
[1]   Distinctions Between Diagnostic and Classification Criteria? [J].
Aggarwal, Rohit ;
Ringold, Sarah ;
Khanna, Dinesh ;
Neogi, Tuhina ;
Johnson, Sindhu R. ;
Miller, Amy ;
Brunner, Hermine I. ;
Ogawa, Rikke ;
Felson, David ;
Ogdie, Alexis ;
Aletaha, Daniel ;
Feldman, Brian M. .
ARTHRITIS CARE & RESEARCH, 2015, 67 (07) :891-897
[2]  
[Anonymous], 2009, Oxford Centre for Evidence-Based Medicine: Levels of Evidence
[3]   Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS) [J].
Araujo, Ariane G. S. ;
Borba, Helena H. L. ;
Tonin, Fernanda S. ;
Lenzi, Luana ;
Venson, Rafael ;
Pontarolo, Roberto ;
Wiens, Astrid .
BIODRUGS, 2018, 32 (04) :377-390
[4]   Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFα Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients [J].
Arstikyte, Inesa ;
Kapleryte, Giedre ;
Butrimiene, Irena ;
Venalis, Algirdas .
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[5]   Immunogenicity of TNF-Inhibitors [J].
Atiqi, Sadaf ;
Hooijberg, Femke ;
Loeff, Floris C. ;
Rispens, Theo ;
Wolbink, Gerrit J. .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[6]   Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis [J].
Bader-Meunier, Brigitte ;
Krzysiek, Roman ;
Lemelle, Irene ;
Pajot, Christine ;
Carbasse, Aurelia ;
Poignant, Sylvaine ;
Melki, Isabelle ;
Quartier, Pierre ;
Choupeaux, Laure ;
Henry, Elodie ;
Treluyer, Jean-Marc ;
Belot, Alexandre ;
Hacein-Bey-Abina, Salima ;
Urien, Saik .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (06) :1014-1018
[7]   Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis [J].
Baeten, Dominique ;
Sieper, Joachim ;
Braun, Juergen ;
Baraliakos, Xenofon ;
Dougados, Maxime ;
Emery, Paul ;
Deodhar, Atul ;
Porter, Brian ;
Martin, Ruvie ;
Andersson, Mats ;
Mpofu, Shephard ;
Richards, Hanno B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) :2534-2548
[8]   Immunogenicity and skin clearance recapture in clinical studies of brodalumab [J].
Bagel, Jerry ;
Lebwohl, Mark ;
Israel, Robert J. ;
Jacobson, Abby .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) :344-351
[9]   Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [J].
Bai, Fan ;
Li, Gang Gang ;
Liu, Qingmin ;
Niu, Xinwu ;
Li, Ruilian ;
Ma, Huiqun .
JOURNAL OF IMMUNOLOGY RESEARCH, 2019, 2019
[10]   Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study [J].
Bartelds, G. M. ;
Wijbrandts, C. A. ;
Nurmohamed, M. T. ;
Stapel, S. ;
Lems, W. F. ;
Aarden, L. ;
Dijkmans, B. A. C. ;
Tak, P. P. ;
Wolbink, G. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (05) :817-821
12345678910